Mammography Should Be Done On Time

Mammography Should Be Done On Time.
Breast cancer patients who have mammograms every 12 to 18 months have less casual of lymph node involvement than those who shelved longer, therefore improving their outlook, according to an betimes new study. As breast cancer progresses, cancer cells may span to the lymph nodes and other parts of the body, requiring more extensive treatment capsule. "We found doing mammograms at intervals longer than one and a half years essentially does adopt patient prognosis," said swotting researcher Dr Lilian Wang.

And "In our study, those patients were found to have a significantly greater lymph node positivity". From 2007 to 2010, Wang evaluated more than 300 women, all of whom were diagnosed with core cancer found during a practice mammogram penis enhancement. She divided them into three groups, based on the delay between mammograms: less than one and a half years, one and a half to three years or more than three years.

Most women were in the blue ribbon category. Wang looked to see how many women had cancer that had spread to their lymph nodes. Although nearly 9 percent of those in the shortest interstice had lymph node involvement, 21 percent of those in the mid-section group and more than 15 percent in the longest-interval group did. The stage at which the cancer was diagnosed did not be dissimilar among the groups, she found.

Although the study found an association between more frequent screenings and less lymph node involvement amid breast cancer patients, it did not establish a cause-and-effect relationship. Wang, an aide professor of radiology at Northwestern University's Feinberg School of Medicine, is scheduled to present the findings Wednesday at the annual gathering of the Radiological Society of North America, in Chicago. The best interlude between routine mammograms has been a point of discussion and debate for years.

A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer

A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer.
A additional chemotherapy tranquillizer made from a pond sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The encouraging finding on the drug, known as eribulin, was presented Sunday at the annual get-together of the American Society of Clinical Oncology in Chicago. "We have a major need for unknown therapies," noted study author Dr Christopher Twelves herbaltor men. "We see a statistically significant promote in overall survival in a situation where we rarely see this sort of improvement".

So "Eribulin targets the mechanisms by which the cells divide, which is several from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and conduct of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to experience either eribulin or a "treatment of physician's choice," the survive because there isn't a standard therapy for this type of cancer naturomax. In almost all cases, it was another chemotherapy.

The study included women who had already been treated extensively for their cancer, with the customary patient already having undergone four chemotherapies. The researchers appear a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin body at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially seat eribulin as a new and effective treatment for women with heavily pretreated knocker cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.

Also featured at the convocation Sunday, Italian researchers report that liver biopsies can disclose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor station or HER2 status. These tumor properties often dictate the type of treatment a woman receives, spirit that some women may benefit from switching therapy if the characteristics of their cancer change.